Adenovirus-mediated suicide gene therapy for experimental bladder cancer

Urology

Volumn 49, Issue 2, 1997, Pages 173-180

  Sutton, Mark A ^b   Berkman, Scott A ^b   Chen, Shu Hsia ^b   Block, Andreas ^b   Dang, Truong D ^b   Kattan, Michael W ^b   Wheeler, Thomas M ^b   Rowley, David R ^b   Woo, Savio L C ^b   Lerner, Seth P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; SURVIVAL TIME; TRANSCRIPTION REGULATION;

ADENOVIRIDAE; ANIMALS; CARCINOMA, TRANSITIONAL CELL; FEASIBILITY STUDIES; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C3H; SIMPLEXVIRUS; THYMIDINE KINASE; URINARY BLADDER NEOPLASMS;

EID: 0031024320     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00560-2     Document Type: Article

References (48)

1. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580, 1992.
2. Lerner SP, and Skinner DG: Radical cystectomy for bladder cancer, in Vogelzang NJ, Shipley WU, Scardino PT, and Coffey DS (Eds): Comprehensive Textbook of Genitourinary Oncology. Philadelphia, Williams & Wilkins, 1996, pp 442-463.
3. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, and Torti FM: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 3: 1463-1470, 1985,
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
5. Kozarsky KF, and Wilson JW: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 3: 499-503, 1993.
6. Sanda MG, and Simons JW: Gene therapy for urologic cancer. Urology 44: 617-624, 1994.
7. Feng M, Cabrera G, DeShane J, Scanlon KJ, and Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55: 2024-2028, 1995.
8. Harris MP, Sutjipto S, Wills FN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, and Maneval DC: Adenovirus mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 3: 121-130, 1996.
9. Seigne JD, Hu S-X, Kong K-T, Zhou Y, Benedict WF, and Xu H-J: Rationale and development of retinoblastoma (RB) tumor suppressor gene therapy for bladder cancer (abstract). J Urol 155: 320A, 1996.
10. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, and Shaked A: Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 155: 753-756, 1996.
11. Connor J, Bannerji R, Saito S, Heston W, Fair W, and Gilboa E: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. [ Erratum: J Exp Med 177: June 1, 1993]. J Exp Med 177: 1127-1134, 1993.
12. Mulligan RC: The basic science of gene therapy. Science 260: 926-932, 1993.
13. Mufson MA, and Belshe RB: A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol 115: 191-194, 1976.
14. Matthews T, and Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10: S490-S494, 1988.
15. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
16. Samejima Y, and Meruelo D: "Bystander killing" induces apoptosis and is inhibited by forskolin. Gene Therapy 2: 50-58, 1995.
17. Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH, and Blaese RM: In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
18. Borrelli E, Heyman R, Hsi M, and Evans RM: Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 85: 7572-7576, 1988.
19. Moolten FL, and Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 84: 297-300, 1990.
20. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, and Breakefield XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of herpes simplex virus thymidine kinase gene. New Biol 3: 608-614, 1991.
21. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, and Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024-7028, 1993.
22. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, and Anbraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
23. Chen SH, Shine HD, Goodman JC, Grossman RG, and Woo SLC: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054-3057, 1994.
24. O'Malley BW, Chen S-H, Schwartz MR, and Woo SL: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 55: 1080-1085, 1995.
25. Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, and Thompson TC: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7: 515-523, 1996.
26. Barba D, Hardin J, Sadelain M, and Gage FH: Development of anti-tumor immunity following thymidine kinasemediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348-4352, 1994.
27. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, and Woo SL: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92: 2577-2581, 1995.
28. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, and Albelda SM: Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3: 85-92, 1996.
29. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, and Shine HD: Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci 39: 506-511, 1994.
30. Vile RG, Nelson JA, Castleden S, Chong H, and Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the hsv-tk gene involves an immune component. Cancer Res 54: 6228-6234, 1994.
31. Ram Z, Culver KW, Walbridge S, Blaese RM, and Old-field EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83-88, 1993.
32. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, and Oldfield EH: The effect of thymidine kinase and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81: 256-260, 1994.
33. Culver KW, Lamsam J, Stratton J, Bennett M, and Seregina T. Molecular surgery for solid tumors. Gene Therapy and Molecular Medicine Conference, Steamboat Springs, Colorado, March 26-April 1, 1995.
34. Graham FL, and Pevec L: Manipulation of adenovirus vectors, in Murray EJ (Ed): Methods in Molecular Biology: Gene Transfer and Expression Protocols. Clifton, NJ, Humana Press, 1991, pp 109-128.
35. Stratford-Perricaudet LD, Makeh I, Perricaudet M, and Perricaudet B: Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90: 626-630, 1992.
36. Goodman JC, Trask TW, Chen S-H, Woo SLC, Grossman RG, Carey KD, Hubbard GB, Carrier DA, Rajagopalan S, Agujilar-Cordova E, and Shine HD: Adenoviral-mediated thymidine kinase gene transfer into primate brain followed by systemic ganciclovir: pathologic, radiologic and molecular studies. Hum Gene Ther 7: 1241-1250, 1996.
37. Soloway MS, deKernion JB, Rose D, and Persky L: Effect of chemotherapeutic agents on bladder cancer: a new animal model. Surg Forum 24: 542-544, 1973.
38. Janik P, Briand P, and Hartman NR: The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35: 3698-3704, 1975.
39. Bi WL, Parysek LM, Warnick R, and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther 4: 725-731, 1993.
40. Cordier L, Duffour MT, Sabourin J-C, Lee MG, Cabannes J, Ragot T, Perricaudet M, and Haddada H: Complete recovery of mice from a preestablished tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2: 16-21, 1995.
41. Wilson JM: Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 1185-1187, 1996.
42. Englehardt JF, Simon RH, Yang Y, et al: Adenovirusmediated transfer of the CFTR gene to lung of non-human primates: biological efficacy study. Hum Gene Ther 4: 759-769, 1993.
43. Ishibashi S, Brown MS, Goldstein JL, et al: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893, 1993.
44. Jaffe HA, Daniel C, Longenecker G, et al: Adenovirusmediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1: 372-378, 1992.
45. Simon RH, Englehart JF, Yang Y, et al: Adenovirus-mediated transfer of the CFTR gene to the lung of non-human primates: toxicity study. Hum Gene Ther 4: 771-780, 1993.
46. Yang Y, Nunes FA, Berensci K, et al: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Nail Acad Sci USA 91: 4407-4411, 1994.
47. Elshami AA, Kucharczuk JC, Sternman DH, Smythe WR, Hwang HC, Amin KM, Litzky LA, Albelda SM, and Kaiser LR: The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 222: 298-310, 1995.
48. Leach DR, Krummel MF, and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.